This study was designed to broaden current knowledge of clinical characteristics and overall survival (OS) of patients with ALK fusion-positive solid tumors (excluding NSCLC) in a real-world setting, using data from clinical practice, and to characterize the prognostic value of the biomarker in the tumor-agnostic context. Here, ALK is linked to non-small cell lung carcinoma.